Physician profile
Mark Dahle
NPI 1174187587
$1,515.50
in general payments reported to CMS, 2019-2025
15 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.99 · 2022: $12.13 · 2023: $424 · 2024: $707 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $474.07 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $251.45 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $187.26 | 2023-2025 | |
| Exact Sciences Corporation | $132.14 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.98 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $78.85 | 2023 | |
| Novo Nordisk INC | $56.72 | 2023-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $54.78 | 2019-2025 | Rotateq, Gardasil 9, Enflonsia |
| Dexcom, INC. | $52.66 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $28.73 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Ucb, INC. | $20.89 | 2025 | Bimzelx |
| Glaxosmithkline, LLC. | $14.94 | 2024 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $14.53 | 2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $13.71 | 2023 | Xarelto |
| Corium, LLC | $12.79 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dahle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.